Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

• the present invention relates to a new application
• Carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds are described as anticonvulsants and antiepileptics in particular in patent EP 50589.
• these compounds can also be used in the treatment of neurological lesions linked to traumas and, in particular, to spinal, cranial or cranio-spinal traumas.
• carbamazepine and oxcarbazepine decrease the neurological deficit of the animals (paraplegia) linked to the lesion of the spinal cord as well as the histopathological lesions (necrosis of the cord). 5 This reduction is generally equal to or greater than 5%.
• PES somesthesic evoked potentials
• the trauma is carried out by inflating the balloon of a Fogarty French 3 probe placed in the spinal canal in the extradural position. For this, we perform a low lumbar laminectomy. The opening of the yellow ligament allows the passage of the probe up to the level of the first lumbar vertebra and the operating wound is closed. A new PES is recorded to ensure that there is no functional lesion during the passage of the probe. The lesion is then carried out by inflating the balloon with variable amounts of air (0.2; 0.4 and 0.55 ml of air) then the probe is removed. A new PES is performed just after the trauma and is compared (amplitudes and latencies) to the reference PES.
• the products are injected intraperitoneally once a day for 5 days, at doses between 1 and 8 mg / kg.
• e) histology a spinal cord block is taken comprising the injured level which is placed in 10% formalin. A week later, the cord is extracted from the block (this fixation period seems necessary to avoid post-mortem injury). A hemorrhagic area visible to the naked eye shows the level of trauma. Staged histological sections specify the extent of the lesions.
• carbamazepine and oxcarbazepine make it possible to reduce the neurological deficit linked to the lesion of the spinal cord, to protect the sensitive neurological pathways and to decrease the necrotic hemorrhagic zone within the gray substance of the spinal cord. These decreases are generally equal to or greater than 5%.
• carbamazepine and oxcarbazepine improve the neurological score of animals that have suffered a head injury and reduce necrotic lesions. This reduction is generally equal to or greater than 5%.
• salts with mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenolphthalinate, methylene-bis- ⁇ -oxynaphthoate or substitution derivatives of these derivatives.
• mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenolphthalinate, methylene-bis- ⁇ -oxynaphthoate or substitution derivatives of these derivatives.
• the medicaments consist of at least one anticonvulsant chosen from carbamazepine and oxcarbazepine in free form or in the form of an addition salt with a pharmaceutically acceptable acid, in the pure state or in the form of a composition in which it is associated with any other pharmaceutically compatible product, which may be inert or physiologically active.
• the medicaments according to the invention can be used orally or parenterally.
• compositions for oral administration tablets, pills, powders (gelatin capsules, cachets) or granules can be used.
• the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
• these compositions can also include substances other than thinners, for example one or more lubricants such as magnesium stearate or talc, a colorant, a coating (dragees) or a varnish.
• compositions for oral administration there may be used pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
• inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
• These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
• the sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions.
• solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other organic solvents can be used. suitable.
• These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
• the doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 50 and 800 mg per day by the oral route for an adult with unit doses ranging from 25 to 200 mg of active substance and between 25 and 600 mg per day by the intravenous route for an adult with unit doses ranging from 12.5 to 200 mg of active substance.
• the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
• Example A illustrate medicaments according to the invention:
• Tablets containing 50 mg of active product having the following composition are prepared according to the usual technique:
• capsules containing 50 mg of active product having the following composition are prepared:
• a solution for injection containing 10 mg of active product having the following composition is prepared:
• the invention also relates to the process for the preparation of medicaments useful in the treatment of neurological lesions linked to traumas and, in particular, to spinal, cranial or craniospinal traumas, consisting in mixing an anticonvulsant chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds with one or more compatible and pharmaceutically acceptable diluents and / or adjuvants.
• an anticonvulsant chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds with one or more compatible and pharmaceutically acceptable diluents and / or adjuvants.
• the invention also relates to a method of treating a mammal and, in particular a man, presenting neurological lesions linked to traumas and, in particular, to spinal, cranial or craniospinal traumas, comprising the administration of a effective amount of an anticonvulsant selected from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of this compound.

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Neurosurgery (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pain & Pain Management (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Peptides Or Proteins (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Hydrogenated Pyridines (AREA)
• Saccharide Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Data Exchanges In Wide-Area Networks (AREA)
• Crystals, And After-Treatments Of Crystals (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9436652

Family Applications (3)

Family Applications After (2)

Country Status (23)

Families Citing this family (75)

Family Cites Families (10)

• 1992
  • 1992-12-16 FR FR9215148A patent/FR2699077B1/fr not_active Expired - Fee Related
• 1993
  • 1993-12-10 CZ CZ951546A patent/CZ154695A3/cs unknown
  • 1993-12-10 WO PCT/FR1993/001229 patent/WO1994013288A1/fr active IP Right Grant
  • 1993-12-10 AU AU56540/94A patent/AU678795B2/en not_active Ceased
  • 1993-12-10 WO PCT/FR1993/001228 patent/WO1994013298A1/fr not_active Application Discontinuation
  • 1993-12-10 PL PL93309347A patent/PL309347A1/xx unknown
  • 1993-12-10 SK SK785-95A patent/SK78595A3/sk unknown
  • 1993-12-10 KR KR1019950702459A patent/KR950703968A/ko not_active Application Discontinuation
  • 1993-12-10 AU AU56539/94A patent/AU5653994A/en not_active Abandoned
  • 1993-12-10 AT AT94902019T patent/ATE164067T1/de active
  • 1993-12-10 EP EP94902018A patent/EP0674520A1/fr not_active Ceased
  • 1993-12-10 SK SK786-95A patent/SK279759B6/sk not_active IP Right Cessation
  • 1993-12-10 UA UA95062798A patent/UA41906C2/uk unknown
  • 1993-12-10 DE DE69317578T patent/DE69317578T2/de not_active Expired - Lifetime
  • 1993-12-10 CZ CZ951547A patent/CZ154795A3/cs unknown
  • 1993-12-10 HU HU9501753A patent/HUT71812A/hu unknown
  • 1993-12-10 EP EP94902019A patent/EP0674512B1/fr not_active Expired - Lifetime
  • 1993-12-10 JP JP6513878A patent/JPH08504428A/ja active Pending
  • 1993-12-10 JP JP6513879A patent/JPH08504429A/ja active Pending
  • 1993-12-10 US US08/424,529 patent/US5830907A/en not_active Expired - Lifetime
  • 1993-12-10 DK DK94902019.2T patent/DK0674512T3/da active
  • 1993-12-10 PL PL93309348A patent/PL309348A1/xx unknown
  • 1993-12-10 RU RU95114405A patent/RU2142800C1/ru not_active IP Right Cessation
  • 1993-12-10 EP EP94902802A patent/EP0674518A1/fr not_active Withdrawn
  • 1993-12-10 CZ CZ951545A patent/CZ284420B6/cs not_active IP Right Cessation
  • 1993-12-10 WO PCT/FR1993/001227 patent/WO1994013296A1/fr not_active Application Discontinuation
  • 1993-12-10 PL PL93309346A patent/PL309346A1/xx unknown
  • 1993-12-10 HU HU9501752A patent/HUT71839A/hu unknown
  • 1993-12-10 SK SK787-95A patent/SK78795A3/sk unknown
  • 1993-12-10 CA CA002151603A patent/CA2151603A1/fr not_active Abandoned
  • 1993-12-10 KR KR1019950702460A patent/KR100298808B1/ko not_active IP Right Cessation
  • 1993-12-10 CA CA002151604A patent/CA2151604C/fr not_active Expired - Fee Related
  • 1993-12-10 AU AU57020/94A patent/AU5702094A/en not_active Abandoned
  • 1993-12-10 KR KR1019950702458A patent/KR950703965A/ko not_active Application Discontinuation
  • 1993-12-10 HU HU9501751A patent/HU217133B/hu not_active IP Right Cessation
  • 1993-12-10 ES ES94902019T patent/ES2113635T3/es not_active Expired - Lifetime
  • 1993-12-10 CA CA002151601A patent/CA2151601A1/fr not_active Abandoned
  • 1993-12-10 JP JP51388094A patent/JP3712239B2/ja not_active Expired - Fee Related
  • 1993-12-13 MX MX9307883A patent/MX9307883A/es unknown
  • 1993-12-13 MX MX9307884A patent/MX9307884A/es unknown
  • 1993-12-13 MX MX9307882A patent/MX9307882A/es not_active Application Discontinuation
  • 1993-12-15 ZA ZA939399A patent/ZA939399B/xx unknown
  • 1993-12-15 ZA ZA939401A patent/ZA939401B/xx unknown
  • 1993-12-15 ZA ZA939400A patent/ZA939400B/xx unknown
  • 1993-12-16 IL IL10805293A patent/IL108052A0/xx unknown
  • 1993-12-16 IL IL10805193A patent/IL108051A/en not_active IP Right Cessation
  • 1993-12-16 IL IL10805393A patent/IL108053A0/xx unknown
• 1995
  • 1995-06-06 NO NO952230A patent/NO307027B1/no not_active IP Right Cessation
  • 1995-06-06 NO NO952229A patent/NO952229L/no unknown
  • 1995-06-06 NO NO952228A patent/NO952228D0/no unknown
• 1998
  • 1998-03-19 GR GR970403094T patent/GR3026403T3/el unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events